The global Inhalable Biologics Market is emerging as a high-growth segment within the pharmaceutical and biotechnology industries as healthcare providers and patients increasingly seek non-invasive alternatives to conventional injectable therapies. Inhalable biologics are therapeutic biological products designed to be administered through the respiratory tract, enabling drugs such as proteins, peptides, monoclonal antibodies, vaccines, and gene therapies to reach the lungs or, in some cases, enter systemic circulation.
According to Kings Research, the global Inhalable Biologics Market was valued at USD 3,210.0 million in 2023 and is projected to grow from USD 3,710.4 million in 2024 to USD 10,844.5 million by 2031, registering a strong CAGR of 16.56% during 2024–2031.
The market is being driven by advancements in inhalation technology, increasing prevalence of respiratory diseases, growing demand for patient-friendly drug administration, and expanding research into inhalable therapies for systemic conditions. Innovations in formulation science, aerosol delivery, nanoparticles, smart inhalers, and biologic stabilization are further expanding the commercial potential of this market.
What Are Inhalable Biologics?
Inhalable biologics are biological medicines formulated specifically for delivery through inhalation. Unlike conventional biologic therapies that are frequently administered by injection or infusion, inhalable biologics can potentially provide a needle-free route of administration.
The lungs offer a large surface area, extensive vascularization, and relatively thin barriers for drug absorption. These characteristics make pulmonary delivery attractive for both localized respiratory treatments and selected systemic therapies.
Major categories of inhalable biologics include:
- Proteins and peptides
- Monoclonal antibodies
- Vaccines
- Gene therapy products
- Other biologic therapeutics
Inhalable biologics may be delivered using dry powder inhalers, metered-dose inhalers, nebulizers, or soft mist inhalers. The selection of delivery technology depends on the formulation, therapeutic target, required dose, particle characteristics, and patient requirements.
Key Growth Drivers of the Inhalable Biologics Market
Rising Demand for Non-Invasive Drug Delivery
One of the strongest drivers of the Inhalable Biologics Market is the growing preference for non-invasive drug administration. Injectable biologics can create challenges such as injection pain, needle anxiety, infection concerns, and the need for administration by healthcare professionals.
Inhalable formulations can provide a more convenient alternative for selected therapies, potentially improving patient comfort, treatment adherence, and self-administration.
This advantage is particularly important for chronic diseases that require frequent or long-term treatment. As pharmaceutical companies increasingly focus on patient-centric healthcare, the demand for convenient drug-delivery systems is expected to increase.
Increasing Prevalence of Respiratory Diseases
The rising burden of respiratory diseases is another major factor supporting market growth. Conditions such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and respiratory infections require effective drug delivery directly to the lungs.
Pulmonary delivery can provide localized exposure at the site of disease, potentially improving therapeutic effectiveness while limiting systemic exposure for certain treatments.
The increasing geriatric population and growing prevalence of chronic respiratory diseases are therefore creating significant opportunities for inhalable biologic developers.
Expansion of Biologic Therapies
Biologics have become increasingly important in modern medicine because they can target complex disease pathways with high specificity. However, many biologics are difficult to administer orally because they can be degraded within the gastrointestinal tract.
Inhalation provides another route that may help overcome some limitations associated with oral delivery. Advances in formulation technologies are enabling researchers to investigate pulmonary administration of proteins, peptides, antibodies, vaccines, and gene-based therapies.
Increasing R&D Investment
Pharmaceutical and biotechnology companies are investing heavily in inhalation platforms, formulation development, aerosol technologies, and novel delivery devices.
Strategic partnerships are also accelerating innovation. For example, in January 2025, Iconovo and Lonza announced a collaboration focused on developing spray-dried formulations for an intranasally delivered biologic candidate targeting obesity.
Inhalable Biologics Market Trends
Growing Interest in Inhaled Gene Therapy
Inhaled gene therapy is one of the most promising emerging areas in the market. The approach aims to deliver therapeutic genetic material directly to lung tissue, potentially addressing diseases caused by genetic abnormalities.
Cystic fibrosis is a major area of research because pulmonary delivery could enable therapeutic genes to reach airway epithelial cells directly.
In February 2025, Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium, and Oxford Biomedica announced the initiation of the LENTICLAIR 1 Phase I/II trial for BI 3720931, an inhaled lentiviral vector-based gene therapy for cystic fibrosis.
Development of Inhalable mRNA Therapies
The success of mRNA-based technologies in vaccines has increased interest in applying similar approaches to inhalable medicines.
Delivering mRNA directly to the lungs could provide opportunities for treating respiratory diseases and developing next-generation vaccines. Researchers are investigating formulations that protect fragile mRNA molecules and enable efficient deposition and uptake within the respiratory system.
Although the technology remains at an evolving stage, inhalable mRNA therapies could become an important area of future pharmaceutical development.
Increasing Use of Dry Powder Inhalers
Dry powder inhalers (DPIs) are becoming increasingly attractive for biologic delivery because they can provide portable, propellant-free administration.
Kings Research projects the dry powder inhalers segment to reach USD 4,278.2 million by 2031. Their ease of use, portability, and potential formulation stability are among the factors supporting adoption.
Expansion Beyond Respiratory Diseases
Although respiratory disorders remain a major application area, companies are increasingly investigating inhalable biologics for systemic conditions.
Diabetes is an important example. Inhaled insulin provides an alternative route for delivering insulin and demonstrates how pulmonary administration can extend beyond traditional respiratory medicine.
Kings Research reports that the diabetes segment accounted for 35.26% of the market in 2023 and is projected to reach USD 3,796.7 million by 2031.
Inhalable Biologics Market Segmentation
By Product Type
Based on product type, the market is divided into:
- Proteins & Peptides
- Monoclonal Antibodies
- Vaccines
- Gene Therapy Products
- Others
The proteins and peptides segment generated USD 939.8 million in 2023, making it an important segment of the market. Growth is supported by increasing research into targeted therapies and improvements in inhalable formulation technologies.
Monoclonal antibodies represent another promising category because of their importance in treating complex diseases. Researchers are investigating inhaled antibodies for respiratory disorders and infectious diseases.
Vaccines and gene therapy products represent emerging opportunities with considerable long-term potential.
By Indication
The major indications include:
- Respiratory Diseases
- Infectious Diseases
- Diabetes
- Pain Management
- Others
Respiratory diseases remain a natural target because inhaled therapies can deliver active ingredients directly to the lungs.
However, diabetes has become a particularly important opportunity because pulmonary delivery can offer an alternative to injectable administration for selected therapies.
By Delivery Device
The market is segmented into:
- Dry Powder Inhalers
- Metered-Dose Inhalers
- Nebulizers
- Soft Mist Inhalers
Dry powder inhalers are expected to experience strong growth through 2031. Nebulizers are also important for therapies requiring liquid formulations or specific aerosol characteristics.
The development of specialized inhalers capable of delivering complex biologic formulations accurately will remain essential to market development.
By Distribution Channel
Distribution channels include:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
The hospital pharmacies segment is projected to reach USD 4,721.7 million by 2031, supported by increasing use of specialized biologic treatments in clinical settings.
At the same time, retail and online pharmacies could become increasingly important as inhalable therapies move toward outpatient and self-administration models.
Regional Analysis of the Inhalable Biologics Market
North America
North America held the largest share of the global market in 2023, accounting for 37.47%, equivalent to approximately USD 1,202.7 million.
The region benefits from a strong pharmaceutical and biotechnology ecosystem, substantial R&D investment, advanced healthcare infrastructure, and the presence of major companies developing inhalable therapies.
The United States is particularly important because of its extensive clinical research infrastructure and supportive innovation ecosystem.
Asia-Pacific
Asia-Pacific is expected to be the fastest-growing regional market, with a projected CAGR of 17.22% from 2024 to 2031.
China and India are becoming increasingly important due to pharmaceutical manufacturing growth, expanding healthcare infrastructure, increasing investment in biotechnology, and rising demand for advanced therapies.
The growing elderly population and increasing prevalence of respiratory diseases are also expected to support market expansion.
In India, for example, Cipla received CDSCO approval in December 2024 for the exclusive distribution and marketing of Afrezza, an inhaled insulin product developed by MannKind Corporation.
Europe
Europe represents an important market due to its established pharmaceutical industry, strong clinical research capabilities, and well-developed regulatory framework.
Countries such as Germany, France, the United Kingdom, Italy, and Spain are investing in advanced biologic therapies and drug-delivery technologies.
Middle East, Africa, and Latin America
Emerging regions are expected to provide long-term opportunities as healthcare infrastructure improves and access to innovative therapies expands.
Market development in these regions will depend on healthcare investment, regulatory harmonization, pharmaceutical distribution networks, and affordability.
Regulatory Environment
Inhalable biologics must satisfy stringent requirements because they combine the complexity of biologic medicines with specialized drug-delivery technologies.
In the United States, the FDA regulates these products under relevant pharmaceutical and biologic frameworks. In Europe, the European Medicines Agency and applicable European regulations govern development and approval.
China’s NMPA, Japan’s PMDA, and India’s CDSCO also oversee inhalable biologics within their respective regulatory systems.
Manufacturers must demonstrate product quality, safety, efficacy, stability, dose consistency, device performance, and appropriate pulmonary delivery characteristics.
Challenges in the Inhalable Biologics Market
Formulation Stability
Biologic molecules are often sensitive to environmental and mechanical conditions. Humidity, temperature, shear forces, and aerosolization processes can affect protein structure and therapeutic activity.
Maintaining stability throughout manufacturing, transportation, storage, and administration is therefore a major challenge.
Bioavailability
Ensuring that an inhaled biologic reaches the intended location and provides sufficient therapeutic exposure can be difficult.
The respiratory tract has several natural defense mechanisms that can limit drug deposition and absorption. Developers must optimize particle size, formulation characteristics, device performance, and dosing.
Manufacturing Complexity
Producing inhalable biologics at commercial scale requires sophisticated formulation and manufacturing capabilities. Maintaining consistent product quality while protecting biological activity can increase development costs.
Regulatory Complexity
Because inhalable biologics combine drug and delivery-device considerations, regulatory approval can require extensive clinical, pharmaceutical, and device-related evidence.
Competitive Landscape
The Inhalable Biologics Market is characterized by strong R&D activity, strategic collaborations, clinical development programs, and investments in advanced delivery technologies.
Major companies identified by Kings Research include:
- AstraZeneca
- MannKind Corporation
- Synairgen plc.
- Pulmocide
- Aerogen Ltd.
- Liquidia Corporation
- Nephron Pharmaceuticals Corporation
- InCarda Therapeutics, Inc.
- Agomab Therapeutics
- Acu-Flow Limited
- ReCode Therapeutics
- AATec Medical GmbH
- Avalyn Pharma Inc.
- VERO Biotech
- Spexis Ltd.
Companies are pursuing several strategies, including novel formulation development, clinical trials, strategic partnerships, device collaborations, and expansion into therapeutic areas beyond respiratory diseases.
The market is also seeing increased interest in aerosol and nanoparticle technologies designed to improve drug deposition, stability, and absorption.
Future Outlook
The future of the Inhalable Biologics Market is expected to be shaped by the convergence of biotechnology, advanced formulation science, drug-delivery devices, and personalized medicine.
Inhaled gene therapies and mRNA-based therapies could create entirely new treatment opportunities. Meanwhile, improvements in dry powder formulations, nebulizers, smart inhalers, and aerosol technologies are expected to improve the delivery of complex biologic molecules.
The expansion of inhalable therapies into diabetes, infectious diseases, autoimmune conditions, and other systemic disorders could significantly increase the addressable market.
Strategic partnerships between pharmaceutical companies, biotechnology firms, device manufacturers, and contract development and manufacturing organizations are also expected to accelerate commercialization.
Conclusion
The Inhalable Biologics Market is positioned for rapid expansion as healthcare moves toward patient-centric, non-invasive, and targeted drug-delivery solutions. According to Kings Research, the market is expected to increase from USD 3,710.4 million in 2024 to USD 10,844.5 million by 2031, representing a 16.56% CAGR.
North America currently leads the market, while Asia-Pacific is projected to experience the fastest growth. Proteins and peptides represent a major product category, while dry powder inhalers, inhaled gene therapies, mRNA formulations, and biologics for systemic diseases are creating new opportunities.
As formulation technologies mature and companies overcome challenges related to stability, bioavailability, manufacturing, and regulatory approval, inhalable biologics could become an increasingly important component of next-generation pharmaceutical treatment.
